Laverty joins Eisai
Prior to joining Novartis, Laverty worked in several corporate policy, corporate affairs, and product public affairs positions at Bristol-Myers Squibb Company.
The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.
Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.
Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.